Table 1 Pre-treatment patient characteristics
# | Age | Race | PSA (ng/mL) | T Stage | Gleason Score | Risk Group | Prostate Volume (cc) | AUA | SHIM |
|---|---|---|---|---|---|---|---|---|---|
1 | 60 | Cau | 4.7 | 1c | 3+3 | Low | 53 | 3 | 20 |
2 | 69 | Cau | 6.8 | 1c | 3+4 | Intermediate | 46 | 3 | 14 |
3 | 69 | Cau | 6.1 | 1c | 3+3 | Low | 29 | 9 | 1 |
4 | 60 | Cau | 4.5 | 1c | 3+3 | Low | 21 | 3 | 18 |
5 | 71 | AA | 4.0 | 1c | 2+3 | Low | 31 | 16 | 19 |
6 | 72 | Cau | 5.6 | 1c | 3+3 | Low | 41 | 4 | 1 |
7 | 56 | AA | 5.7 | 1c | 3+3 | Low | 43 | 9 | 16 |
8 | 70 | Cau | 4.9 | 1c | 3+3 | Low | 23 | 4 | 21 |
9 | 74 | Cau | 4.9 | 1c | 3+3 | Low | 45 | 10 | 15 |
10 | 78 | Cau | 8.1 | 2b | 3+3 | Intermediate | 33 | 1 | 3 |
11 | 71 | Cau | 4.9 | 1c | 3+3 | Low | 33 | 5 | 20 |
12 | 58 | AA | 7.9 | 1c | 3+4 | Intermediate | 37 | 12 | 21 |
13 | 66 | Cau | 10.3 | 1c | 3+3 | Intermediate | 34 | 14 | 25 |
14 | 74 | AA | 6.3 | 1c | 4+3 | Intermediate | 55 | 9 | 4 |
15 | 70 | Cau | 6.8 | 1c | 3+3 | Low | 30 | 21 | 20 |
16 | 62 | Cau | 4.0 | 1c | 3+4 | Intermediate | 30 | 1 | 25 |
17 | 79 | Cau | 2.3 | 2b | 3+4 | Intermediate | 52 | 5 | 3 |
18 | 48 | AA | 6.8 | 1c | 3+3 | Low | 18 | 8 | 24 |
19 | 73 | Cau | 6.9 | 1c | 3+4 | Intermediate | 40 | 3 | 4 |
20 | 62 | Cau | 5.6 | 1c | 3+3 | Low | 25 | 6 | 23 |
21 | 63 | AA | 6.2 | 1c | 3+4 | Intermediate | 42 | 4 | 15 |
22 | 69 | AA | 5.8 | 1c | 3+4 | Intermediate | 42 | 6 | 18 |
23 | 71 | AA | 5.9 | 1c | 3+3 | Low | 34 | 2 | 24 |
24 | 65 | Cau | 7.4 | 1c | 4+3 | Intermediate | 33 | 7 | 24 |
25 | 78 | AA | 4.2 | 2b | 4+3 | Intermediate | 37 | 10 | 1 |
26 | 67 | Cau | 4 | 2a | 3+3 | Low | 49 | 5 | 20 |